Please login to the form below

Not currently logged in
Email:
Password:

Delay for inhaled hypertension treatment

United Therapeutics has announced it is likely to face regulatory delays for the inhaled version of its hypertension drug Remodulin

United Therapeutics Corp today announced it is likely to face regulatory delays for the inhaled version of its hypertension drug Remodulin because of Food and Drug Administration (FDA) concerns over patient instructions.

The company had expected a decision from the FDA by April 30, but will likely face delays because of questions over instructions for using the nebuliser that delivers the drug.

United Therapeutics is a biotechnology company focused on the development and commercialisation of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer. The company already sells the drug as an injection called Remodulin. The inhaled version is called Tyvaso.

"Following our most recent discussion with the FDA, we have agreed to conduct human factors testing to validate that the revised instructions for use (IFU) results in the proper use of the device by a naive user," said President and Chief Operating Officer Roger Jeffs, in a statement. "This relatively small study in normal subjects will test the new IFU in its ability to guide patients to accomplish such tasks as proper device assembly, drug administration, disassembly and cleaning, among other things."

Shares of United Therapeutics sank $2 (or 3 per cent) to $66.28 in pre-market activity.

16th March 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics